Stock screener

KLRS

Conviction 4HealthcareScan · Mon, Aug 10, 2026
KLRS$3.95-2.95%
ResistanceSupportVol 14Insider buy
63 bars
5
Vol MA14 93.37K
May 11May 28Jun 16Jul 6Jul 23Aug 10
Kalaris Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.kalaristx.com
Price3.95
Change-2.95%
Gap+0.25%
Rel volume0.07×
Avg volume665.81K
Avg $ vol2.87M
SMA 204.01
SMA 504.30
SMA 2006.52
Price vs 50-8.08%
Price vs 200-39.44%
MA stackbearish
50/200 cross
Supertrenddown · 4.58
RSI (14)46
MACD hist0.06
MACD crossbull · 4d
Stoch %K / %D67 / 72
ADX (14)14
+DI / −DI26 / 21
RSI divergence
MACD divergence
ATR %+9.57%
ADR %11.04%
52w high10.98
52w low2.27
From 52w high-64.03%
Above 52w low+74.01%
New 52w highNo
SqueezeOff
Bollinger width40.16%
%B0.46
Donchian pos28.57%
Donchian high6.25
Donchian low3.03
AVWAP (52w high)5.87
vs AVWAP high-32.66%
AVWAP (52w low)5.66
vs AVWAP low-30.26%
OBV trendDown
Chaikin MF (20)-0.74
Today vs 20d0.07×
Avg vol (14d)93.37K
Avg vol (20d)665.81K
Avg $ vol (20d)2.87M
Market cap93.98M
RS 3m (vs SPY)-26.67%
RS 6m (vs SPY)-65.37%
RS line new highNo
Trend template1/8
Technical rank8.7
1 week-2.47%
1 month-11.04%
3 months-22.24%
6 months-52.64%
1 year+45.76%
YTD-52.41%
P/E-2.16
P/B1.37
P/S569.57
P/FCF-2.44
EPS-2.85
Div yield
ROE-63.36%
ROA-39.56%
Debt/Eq
Current12.19
EV/EBITDA-1.30
Gross margin
Net margin
Rev growth
EPS growth37.20%
Price target
Target upside
Analyst rating
Institutional
Ent. value59.55M
Revenue165K
Net income-10.86M
Gross profit
Free cash flow-38.57M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out23.79M
Employees20
ListedWed, Mar 19, 2025
Free float3.17M
Float %17.0%
Short interest520.19K
Days to cover11.7d
Short volume19.8%
Squeeze score58 / 100
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeD
Conviction4 / 100
Pattern quality
Tech rank8.7 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance5.58
Support3.28
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in KLRS

All disclosures →
No recent disclosed trades by Congress in KLRS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in KLRS · 10 buys

InsiderSideShares
AKKARAJU SRINIVAS
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
Ferrara Napoleone
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
Hallal David
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
ADAMIS ANTHONY P
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
Jovan-Embiricos Morana
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
PATTERSON LEONE D
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
Dybbs Michael
Director · Stock Option (Right to Buy) · 2026-06-03
Grant9K
AKKARAJU SRINIVAS
Director · Common Stock · 2026-05-20
Buy244.3K
AKKARAJU SRINIVAS
Director · Common Stock · 2026-05-20
Acquire14.94K
AKKARAJU SRINIVAS
Director · Common Stock · 2026-05-20
Acquire4.47K

SEC filings

EDGAR filings in KLRS · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.